AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$5.81 USD
+0.03 (0.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.80 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for AngioDynamics, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 | |
---|---|---|---|---|---|
Sales | 339 | 316 | 291 | 264 | 271 |
Cost Of Goods | 165 | 150 | 134 | 114 | 115 |
Gross Profit | 174 | 166 | 157 | 150 | 156 |
Selling & Adminstrative & Depr. & Amort Expenses | 225 | 194 | 192 | 317 | 165 |
Income After Depreciation & Amortization | -51 | -28 | -35 | -167 | -9 |
Non-Operating Income | -1 | -1 | 0 | 0 | 0 |
Interest Expense | 3 | 1 | 1 | 1 | 5 |
Pretax Income | -54 | -30 | -36 | -168 | -15 |
Income Taxes | -2 | -3 | -5 | -1 | -4 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -27 | -32 | -167 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 72 |
Net Income (GAAP) | -52 | -27 | -32 | -167 | 61 |
Depreciation Footnote | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | 1 | -9 | -143 | 16 |
Depreciation & Amortization (Cash Flow) | 45 | 29 | 26 | 24 | 26 |
Income After Depreciation & Amortization | -51 | -28 | -35 | -167 | -9 |
Earnings Per Share Data | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | 5/31/19 |
---|---|---|---|---|---|
Average Shares | 39.48 | 39.01 | 38.34 | 37.96 | 38.15 |
Diluted EPS Before Non-Recurring Items | -0.06 | 0.00 | 0.05 | 0.09 | 0.83 |
Diluted Net EPS (GAAP) | -1.33 | -0.68 | -0.82 | -4.39 | 1.64 |
Fiscal Year end for AngioDynamics, Inc falls in the month of May .
All items in Millions except EPS data.
2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 | |
---|---|---|---|---|---|
Sales | 75.18 | 79.07 | 78.68 | 91.07 | 80.71 |
Cost Of Goods | 39.32 | 38.81 | 38.62 | 44.71 | 40.21 |
Gross Profit | 35.86 | 40.26 | 40.06 | 46.36 | 40.50 |
SG&A, R&D, and Dept/Amort Expenses | 235.76 | 53.38 | 5.03 | 67.20 | 49.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | -199.90 | -13.12 | 35.03 | -20.84 | -8.93 |
Non-Operating Income | 0.16 | 0.50 | -0.17 | -0.13 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.90 | 0.74 |
Pretax Income | -199.74 | -12.62 | 34.86 | -21.87 | -9.66 |
Income Taxes | -12.00 | 16.43 | -11.02 | -0.40 | -0.18 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -187.74 | -29.05 | 45.88 | -21.47 | -9.49 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -187.74 | -29.05 | 45.88 | -21.47 | -9.49 |
Earnings Per Share Data | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 |
---|---|---|---|---|---|
Average Shares | 40.23 | 40.22 | 39.97 | 39.61 | 39.51 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.05 | -0.12 | 0.02 | -0.03 |
Diluted Net EPS (GAAP) | -4.67 | -0.72 | 1.15 | -0.55 | -0.24 |